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Expression of growth-related protooncogenes during diabetic renal
hypertrophy. Experimental type 1 diabetes mellitus is characterized by an
early increase in kidney weight and glomerular volume, but changes in
gene expression accompanying diabetic renal growth have not been
elucidated. The early response genes, c-fos, c-fun, and c-myc encode
proteins that regulate gene transcription, thus influencing the cellular
responses to a stimulus. Accordingly, we studied c-fos, c-fun, and c-myc
expression in glomeruli during the rapid phase of glomerular hypertrophy
that follows the onset of hyperglycemia in diabetic rats. Total RNA was
extracted by the method of Chomczynski from isolated glomeruli of
streptozotocin (60 mg/kg i.v.) induced diabetic rats 24, 48, and 96 hours,
and 1 week after the onset of hyperglycemia (blood glucose >15 mmol/
liter). A second group of rats, studied after streptozotocin administration,
received twice daily insulin to maintain normoglycemia. A group of
age-matched normal rats served as the control group. Northern blot
analysis was performed with eDNA probes for c-fos, c-fun, and c-myc, and
GAPDH. mRNA levels for c-fos increased fourfold 24 hours after the
onset of hyperglycemia, but returned to baseline by 48 hours. mRNA
levels for c-fun increased threefold 24 hours after the onset of hyper-
glycemia, in diabetic glomeruli, and the increase was sustained for one
week. Intensive insulin treatment normalized blood glucose levels and
abrogated the increases in c-fos and c-fun expression. There was no
discernable increase in c-myc mRNA levels in the diabetic glomeruli. We
conclude that the early phase of glomerular growth following the onset of
hyperglycemia in diabetic rats is accompanied by increased c-fos and c-fun
expression.
Recent morphologic studies suggest that structural hypertrophy
is an important determinant of glomerular injury [11, and in-
creases in kidney size and glomerular volume precede glomeru-
losclerosis in patients with type I diabetes mellitus [2, 3]. Studies
of rats with experimental type I diabetes mellitus have shown that
a rapid phase of renal growth follows the onset of hyperglycemia
so that both whole kidney weight and glomerular volume increase
by at least 50% after 10 to 14 days of hyperglycemia [4].
Autoradiography studies by Rasch show no uptake of 3H-thymi-
dine in glomerular cells during this period, while some 3H-
thymidine uptake is evident in tubular cells approximately 96
hours after the onset of hyperglycemia [5]. Overall, the ratio of
kidney RNAIDNA increases, suggesting that early kidney growth
in experimental diabetes occurs predominantly by a process of cell
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hypertrophy [6, 7]. The molecular events underlying this early
phase of diabetic renal growth have not been completely eluci-
dated.
Growth-related protooncogenes, including c-fos, c-jun, and c-myc,
are typically expressed transiently by cells in response to a
stimulus [8—12]. These genes encode proteins that regulate gene
transcription and thus influence the cellular response [8, 9, 12]. In
vitro studies of mesangial cells by Ziyadeh and coworkers have
shown that c-myc is expressed when the cells are exposed to high
glucose concentrations [13], while more recently, Kreisberg and
coworkers have reported that c-fos and c-jun expression increase
in mesangial cells grown in high glucose [141. In the current study,
we sought to determine whether the early phase of diabetic
glomerular hypertrophy in rats with experimental type I diabetes




Male Sprague-Dawley rats (Harlan Bioproducts for Science,
Inc., Indianapolis, IN, USA) weighing 271 to 298 grams received
streptozotocin, 60 mg/kg body weight, via a single tail vein
injection. Age-matched normal rats served as the control group.
Tail samples of blood were obtained every six hours after admin-
istration of streptozotocin for determination of blood glucose
levels with an Ames Accutest Glucometer. After the onset of
hyperglycemia (defined as blood glucose levels greater than 15
mmol/liter), the blood glucose level was measured daily. Rats
were excluded if their blood glucose levels failed to rise above 15
mmol/liter. All of the animals had unlimited access to rat chow
(Purina Rat Chow) and water.
Diabetic rats were studied at 24 hours (N = 10), 48 hours (N =
5), 96 hours (N = 5), and 1 week (N = 5) after the onset of
hyperglycemia. A second group of rats (N = 10) received strep-
tozotocin but were rendered euglycemic by twice daily insulin
treatment and were studied with the 24-hour diabetic rats (ap-
proximately 36 hours after streptozotocin administration). Kidney
weight and glomerular volume were determined in a separate
group of diabetic rats, one week after the onset of hyperglycemia
(N = 4), and in a separate group of rats that received streptozo-
tocin but were rendered euglycemic for one week by twice daily
insulin treatment (N = 4). Age-matched normal rats served as the
control group (N = 14).
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Glomerular isolation
At each time point studied, five rats from each group were
anesthetized with Brietal (50 mg/kg) intraperitoneally and the
kidneys were rapidly removed. Perirenal fat was trimmed off.
After the renal capsule was removed, the cortex was separated
from the medulla. Cortical tissue from five rats was pooled and
placed in ice-cold PBS buffer (pH 7.4), and cut into 8 mm3 pieces.
The glomeruli were isolated from the pooled cortical tissue by the
technique of differential seiving. The tissue was first passed
through a 250 tm sieve and resuspended in ice-cold PBS before
centrifugation at 2000 rpm for 10 minutes at 4°C. The pellet was
resuspended in ice-cold PBS (pH 7.4) and drawn up through a 20
gauge needle and discharged three times, then centrifuged at 2000
rpm for 10 minutes at 4°C. The tissue pellet was resuspended in
ice-cold PBS (pH 7.4) and passed through a 106 im sieve and
then a 72 .tm sieve. Glomeruli collected on the 75 ttm screen and
were finally resuspended in ice-cold PBS (p1-1 7.4). All solutions
were DEPC-treated. The purity of the final suspension was
determined by light microscopic examination. On average, there
were fewer than five tubular fragments per 100 glomeruli. The
suspension of glomeruli was then used for RNA isolation.
RNA isolation
Total RNA from glomeruli was extracted by the single step
method of Chomzynsky [15]. Two milliliters of a solution contain-
ing 4 M guanidinium isothiocyanate and 0.1 M 2-mercaptoethanol
were added to the glomerular suspension and vortexed; 0.2 ml of
2 M Na acetate, 2.0 ml of DEPC-treated phenol, and 0.4 ml of
chloroform were then added. The solution was placed on ice for
15 minutes and then centrifuged at 8000 rpm for 20 minutes. An
equal volume of isopropanol was added to the aqueous phase and
precipitated at —20°C for at 60 minutes. Total RNA was pelleted
by centrifugation at 8000 rpm for 20 minutes, resuspended in 300
p1 of a solution containing 4 M guandinium isothiocyanate and
0.1 M 2-mercaptoethanol and 300 p1 of isopropanol, and again
precipitated at —20°C for 60 minutes. After centrifugation, the
RNA pellet was resuspended in 300 p1 of cold 70% ethanol and
stored in DEPC-treated water at —70°C. The purity and concen-
tration was determined by measuring the optical densities at 260
and 280 nm prior to use. The A26/A280 ranged from 1.75 to 1.95.
Northern blot analysis
Twenty ig of total RNA was separated by electrophoresis on
1.5% agarose formaldehyde gels containing ethidium bromide,
transferred to a nylon filter (Hybond N), and cross-linked by UV
illumination. The eDNA probes used were rat c-fos (a gift from
Dr. Andre Schuh, University of Toronto), rat c-myc (a gift of Dr.
Linda Penn, Hospital for Sick Children, University of Toronto),
and human GAPDH (a gift from Dr. Phillip Marsden, University
of Toronto). v-jun (a gift from Dr. Andre Schuh, University of
Toronto) was digested with ECOR1 and XBA to yield a 1.8 kB
insert that corresponded to c-jun.
cDNA probes were radiolabeled by random oligolabeling using
DNA polymerase I (T7 Quickprime Kit, Pharmacia) in the
presence of 32P dCTP (3000 Ci/mmoi). 32P dCTP-labeled eDNA
probes were separated from unincorporated nucleotides by gel
filtration with Sephadex G-50 (Nick Columns, Pharmacia LKB
Biotechnology). The membranes used were prehybridized for 15
minutes at 65°C in 10 ml of QuikHybTM Rapid Hybridization
Solution (Stratagene). For hybridization, the radiolabeled probe
(total counts, 106 cpm) and 100 p1 (50 mg/mi) of salmon sperm
DNA were added to this solution for one hour at 65°C. The
membranes were washed three times. The first wash was 2X
SSC/0.1% SDS at room temperature, followed by 2X SSC/0.1%
SDS at 40°C. The final wash was lx SSC/0.1% SDS at 40°C. The
radioactivity emitted by the filters was monitered during washing
with a hand-held beta-emission counter. Filters were then exposed
to x-ray film at —70°C with two intensifying screens (FisherScien-
tific) for 24 to 72 hours. Filters were stripped with two sequential
washes of boiling lx SSC/0.1% SDS for 15 minutes for subse-
quent hybridization to the filter.
The autoradiograms were quantitated with a GS 300 Transmit-
tance/Reflectance Scanning Densitometer (Hoefer Scientific In-
struments) utilizing a MacIntosh Classic II (System 7.0) and Dy-
namax HPLC Method Manager (V1.2).
Mean glomerular volume
Glomerular tuft volume (V0) was determined by measuring the
mean glomerular cross-sectional area (A0) of all glomerular
profiles in cryostat sections in normal rats, diabetic rats one week
after the onset of hyperglycemia, and rats that received strepto-
zotocin and insulin to normalize blood glucose levels.
Four rats from each group were anesthetized with Brietal (50
mg/kg) intraperitoneally, and the kidneys were rapidly removed.
Perirenal fat was trimmed off, and the cortex was separated from
the medulla. Small blocks of cortical tissue were snap frozen in
liquid nitrogen. Five micron thick cryostat sections were mounted
on poly-l-lysine coated slides, and stained with hemotoxylin and
eosin [32]. A 100 point grid was superimposed over each glomer-
ular profile. Each point represented 625 i2. The number of points
overlying each profile were enumerated, and the mean profile
area (AG) was calculated from a minimum of 25 glomerular
profiles (range 25 to 41). Mean glomerular volume was calculated
from AG by the method of Weibel [16]:
13 (AG)31 — _________ 3
VG k
where 13 = 1.38 is the shape coefficient for spheres (the idealized
shape of glomeruli) and k = 1.1 is a size distribution coefficient.
Analysis
The densitometty data was normalized to the value obtained for
the normal rats. The statistical significance of differences among
values of individual parameters was assessed with ANOVA.
Significance was defined as P < 0.05.
Results
Body weight and blood glucose levels
Streptozotocin was administered to rats weighing an average of
276 6 grams. Over the course of the experiment, diabetic rats
lost weight so that by one week, the mean body weight decreased
to 235 10 grams. The average blood glucose levels for normal
rats was 4.7 .1 mmol/liter. Hyperglycemia was defined as a
blood glucose level greater than 15 mmol/liter. Twenty-four hours
after the onset of hyperglycemia, blood glucose levels averaged
18.4 1.7 mmol/Iiter. The average blood glucose level was 16.8
1.4 mmol/liter 48 hoursafter the onset of hyperglycemia, and 17.6
Normal DM DM-RX
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Fig. 1. Kidney weight in age-matched normal rats (Normal), diabetic rats
one week after the Onset of hypelycemia (DM), and rats that received
streptozotocin and insulin to maintain normoglycemia (DM-Rx). *p < 0.05
vs. Normal. < 0.05 vs. DM.
1.9 mmol/liter after 96 hours. Mean values exceeded 22
mmol/liter at one week. Intensive insulin treatment normalized
blood glucose values, so that the mean blood glucose level was less
than 6 mmollliter at each time point.
Kidney weight and glomerular volume
This experimental model of type I diabetes mellitus is associ-
ated with an early increase in kidney size. After one week of
hyperglycemia, whole kidney weight averaged 1.55 .04 grams in
untreated diabetic rats compared to 1.21 .08 grams in normal
rats (P < 0.05). The increase in whole kidney weight was
accompanied by a significant increase in glomerular volume in the
diabetic rats compared to the age matched normal rats (Fig. 1).
The mean value for glomerular volume (VG) was 0.97 0.05
in normal rats and 1.41 .10 106jj3 in diabetic rats (P <
0.05; Fig. 2). As expected, mean values for kidney weight (1.28
0.05 grams) and glomerular volume (1.05 .06 106p?) were
normalized by intensive insulin treatment (Figs. 1 and 2, respec-
tively).
Northern blot analysis
Twenty-four hours after the onset of hyperglycemia, mRNA
levels for c-fos increased nearly fourfold in diabetic glomeruli,
compared to glomeruli from normal rats. The increase in c-fos
mRNA was not sustained, and mRNA levels were comparable to
those obtained in normal glomeruli by 48 hours. The Northern
blot analysis for c-fos mRNA levels is shown in Figure 3A. Figure
3C shows the Northern blot analysis for the housekeeping gene,
GAPDH. The ratios for the densitometry measures of c-fos
mRNA levels and GAPDH mRNA levels are depicted in Figure
4. The ratio for the normal rats was assigned a value of one, and
represents a mean value for five normal rats because renal cortical
tissue from five rats (10 kidneys) was pooled for glomerular
isolation and extraction of RNA. Similarly, at each time point, the
ratios depicted for the hyperglycemic diabetic rats represent mean
values for five diabetic rats because the ratios are derived from
Fig. 2. Glomendar volume in age-matched normal rats (Normal), diabetic
rats one week after the onset of hypeilycemia (DM), and rats that received
streptozotocin and insulin to maintain normoglycemia (DM-Rs). < 0.05
vs. Normal. < 0.05 vs. DM.
measures of mRNA levels that were obtained using RNA from
the pooled glomeruli of 10 kidneys from five diabetic rats.
Twenty-four hours after the onset of hyperglycemia, mRNA
levels for c-jun increased 3.5-fold in diabetic glomeruli, but unlike
c-fos mRNA, c-jun mRNA levels remained elevated 48 hours, 96
hours and one week after the onset of hyperglycemia. The
Northern blot analysis for c-jun mRNA levels is shown in Figure
3B, while Figure 3C shows the Northern blot analysis for the
housekeeping gene, GAPDH. The ratios for the densitometiy
measures of c-jun mRNA levels and GAPDH mRNA levels are
depicted in Figure 5. The control value again represents a mean
value for five normal rats, and the ratios depicted for the
hyperglycemic diabetic rats represent mean values for five diabetic
rats.
Basal expression of c-myc was low in normal glomeruli so that
mRNA levels for c-myc were barely detectable. No increase in
mRNA levels was detectable in diabetic glomeruli compared to
normal glomeruli, at any of the time points examined (results not
shown).
To determine if the changes in c-fos and c-jun expression in
glomeruli were dependent on the development of hyperglycemia,
further experiments were carried out in hyperglycemic diabetic
rats and in rats that received streptozotocin but were treated with
twice daily insulin to maintain normal blood glucose levels. Figure
6 shows the Northern blot analyses for c-fos, c-jun, and GAPDH
mRNA levels in glomeruli from separate groups of normal (lane
1) and hyperglycemic diabetic rats (lane 2). Twenty-four hours
after the onset of hyperglycemia, c-fos and c-jun mRNA levels
were increased. The analysis was performed on RNA from
glomeruli isolated from pooled kidneys from five normal and five
diabetic rats.
Figure 7 shows the Northern blot analysis for c-fos and GAPDH
mRNA levels, respectively, in glomeruli from normal rats (lane 1)
and rats that received streptozotocin but remained normoglyce-
mic because of early insulin treatment (lane 2). The increase in
c-fos mRNA levels observed in the glomeruli of hyperglycemic
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Fig. 3. Northern blot analysis for c-fos mRNA
levels (A), c-jun mRNA levels (B), and GAPDH
mRNA levels (C) in glomeruli of normal rats and
diabetic rats 24 hours, 48 hours, 96 hours, and
one week after the onset of hyperglycemia.
0
Normal 24 hr
Fig. 4. The effect of hyperglycemia on steady state levels of mRNA for c-fos
in glomeruli from normal (C) and hyperglycemic diabetic rats, 24 hours, 48
hours, 96 hours, and one week after the onset of hyperglycemia. The
densitometry measures (O.D.) were normalized so that the ratio of
c-fos/GAPDH obtained in normal rats was assigned a value of 1.0,
the development of hyperglycemia. Figure 8 shows the Northern
blot analysis for c-jun and GAPDH mRNA levels, respectively,
in glomeruli from normal rats (lane 1) and rats that received
streptozotocin but remained normoglycemic (lane 2). The in-
crease in c-jun mRNA levels observed in the glomeruli of
hyperglycemic diabetic rats was also abrogated by insulin treat-
ment.
Discussion
Type I diabetes mellitus is characterized by an early increase in
kidney weight and glomerular volume [2—5], but the molecular
events responsible for diabetic glomerular growth have not been
completely elucidated. Like the increase in glomerular volume
following uninephrectomy [5], the early phase of diabetic glomer-
ular growth is characterized by cell hypertrophy [5—7]. However,
0
Normal 48 hr 96 hr 1 week
Fig. 5. The effect of hyperglycemia on steady state levels of mRNA for c-jun
in glomendi from normal (C) and hyperglycemic diabetic rats, 24 hours, 48
hours, 96 hours, and one week after the onset of hyperglycemia. The
densitometry measures (O.D.) were normalized so that the ratio of
c-fos/GAPDH obtained in normal rats was assigned a value of 1.0.
diabetic glomerular hypertrophy is followed by progressive gb-
merular injury, unlike compensatory gbomerular hypertrophy [17],
and it is tempting to speculate that early molecular events might
account, in part, for this difference.
Growth-related protooncogenes are nuclear proteins that act as
transcription factors, and increased protooncogene expression is
an early intracellular event that may determine, in part, the
cellular response to a stimulus [8—12]. A number of investigators
have studied protooncogene mRNA levels in the kidney during
the early phase of compensatory renal hypertrophy that follows
uninephrectomy [8—23], but only one study, by Nakamura and
coworkers, examined protooncogene expression in gbomeruli [19].
No changes in c-fos, c-jun, or c-myc mRNA levels were detectable
in gbomeruli at time points that ranged from one hour to one week
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NG DG24 DG24
Fig. 7. Northern blot analysis for c-fos mRNA levels (A) and GAPDH
mRNA levels (B) in glomeruli of normal rats (NG) and rats that received
streptozotocin and insulin to maintain normoglycemia for 24 hours (DG24).
c-fos, c-jun, and c-myc mRNA levels renal cortical tissue within 12
hours of uninephrectomy [19]. Since compensatory glomerular
hypertrophy is not associated with changes in c-fos, c-fun, and
c-myc expression, the major aim of the current study was to
determine whether the early phase of glomerular hypertrophy in
rats with experimental type I diabetes mellitus was accompanied
by changes in growth-related protooncogene expression.
Northern blot analysis of glomerular protooncogene mRNA
levels was performed from 24 hours to one week after the onset of
hyperglycemia because kidney weight and glomerular volume
increase rapidly in diabetic rats during this period [4]. Our first
major observation was that c-fos mRNA levels increased 24 hours
after the onset of hyperglycemia, defined as a blood glucose above
15 mmol/liter. We further observed that the increase in c-fos was
transient. When glomeruli were isolated from diabetic rats 48
hours after the onset of hyperglycemia, c-fos mRNA levels were
no longer elevated. This pattern is typical of c-fos and is in accord
with in vitro studies showing that c-fos represses it's own promoter
so that increased expression is characteristically transient [24].
Transient expression is also consistent with a recent report by
Kreisberg and coworkers [14]. Fifteen to thirty minutes after
mesangial cells were exposed to medium containing 30 mM
glucose, there was a 1.6-fold rise in c-fos mRNA levels. After 60
minutes in 30 mrvi glucose, c-fos mRNA levels in mesangial cells
returned to normal. The onset of the increase in c-fos expression
differed in our study, but may have reflected the lower glucose
concentration in the diabetic rats in vivo compared to the in vitro
studies with mesangial cells.
Our second major observation was that there was an increase in
c-jun mRNA levels 24 hours after the onset of hyperglycemia in
glomeruli. In contrast to the changes in c-fos mRNA levels, c-jun
mRNA levels remained elevated 48 hours, 96 hours, and one week
after the onset of hyperglycemia in diabetic glomeruli compared
to normal glomeruli. Sustained expression of c-fun in response to
a stimulus is typical [25], and Kreisberg et al also showed a
sustained rise in c-fun mRNA in mesangial cells exposed to 30 mrvi
glucose [14].
To address the concern that early changes in protooncogene
expression might be due to streptozotocin-induced glomerular
injury rather than hyperglycemia, experiments were performed in
rats that received streptozotocin and insulin to prevent the
development of hyperglycemia. We observed that c-fos and c-fun
mRNA levels did not increase in rats that received both strepto-
zotocin and insulin to maintain normoglycemia, thus establishing
that the early increase in c-fos and c-fun expression was not a
simple consequence of streptozotocin toxicity, but rather was
dependent on the development of hyperglycemia because insulin
treatment prevented the rise.
The relationship between early increases in protooncogene
mRNA levels and glomerular injury remains speculative. c-fos and
c-fun are members of the APi family of transcription factors [26,
27], and the c-fos and c-fun proteins modulate gene transcription
by forming a heterodimer which binds to consensus DNA se-
quences in the regulatory elements of genes called API or
TPA-responsive sites [28, 29]. Thus, an early increase in c-fos and
c-fun expression may lead to an increase in transcription of genes
regulated by TPA-responsive sites [30]. Moreover, a concurrent
rise in c-fos and c-fun mRNA in glomerular cells is functionally
important because the heterodimer c-foslc-fun binds more avidly
to the TPA-responsive site than the fun/fun homodimer [31].
We have reported that TGF-f31 mRNA levels increase in
glomeruli during the early phase of diabetic glomerular hypertro-
phy [32]. The promoter of the TGF-f31 gene contains an APi or
TPA-responsive consensus sequence [33, 34], so that it is tempting
to speculate that early increases in c-fos and c-fun levels in
glomerular cells are responsible, at least in part, for the subse-
quent rise in TGF-f31 mRNA levels in diabetic glomeruli. A
sustained increase in TGF-pI in diabetic glomeruli, which has
been reported by Yamamoto and coworkers [35], would then lead
to cell hypertrophy [36] and an increase in extracellular matrix
Fig. 6. Northern blot analysis for c-fos mRNA levels (A), c-jun mRNA levels
(B), and GAPDHmRNA levels (C) in glomeruli of normal rats and diabetic
rats 24 hours after the onset of hypeiglycemia.
A B
NC
Fig. 8. Northern blot analysis for c-jun mRNA levels (A) and GAPDH
mRNA levels (B) in glomeruli of normal rats (C) and rats that received
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protein production, linking hypertrophy and injury in the glomer-
ulus [37—41]. Although this pathway is simplistic because of the
known interaction between APi transcription factors and other
families of transcription factors, including the cAMP-responsive
element binding proteins [42, 43], experiments with antisense
c-fos/c-jun oligonucleotides should establish if there is an impor-
tant link between c-foslc-jun and TGF-J31 expression. In addition,
Kreisberg et al have noted that there are APi orTPA-responsive
consensus sequences in the promoter elements of the fibronectin
gene and the laminin B gene, a pathway that would also link
c-foslc-jun expression directly to extracellular matrix protein ex-
pression [14].
The mechanism by which hyperglycemia leads to an increase in
c-fos mRNA levels was not addressed in the current study.
However, an attractive hypothesis is that the effects of hypergly-
cemia are mediated by protein kinase C. In vitro, protein kinase C
(PKC) activity increases in mesangial cells exposed to high glucose
concentrations [44, 45], and PKC activity is increased in glomeruli
[46] and renal cortical tissue of diabetic rats [47]. PKC activity can
directly regulate expression of c-fos mRNA [30, 48—51]. Thus,
hyperglycemia-induced increases in PKC activity in glomerular
cells in vivo may be responsible for the observed changes in
protooncogene expression. Further studies are necessary to test
this hypothesis.
In contrast to the changes in c-fos and c-jun mRNA levels, we
were unable to demonstrate any change in c-myc mRNA levels in
the glomeruli of hyperglycemic rats at any of the time points
examined. c-myc expression is high in actively proliferating cells
and this generally corresponds to the late GuS phase of the cell
cycle [9, 12]. 3H-thymidine uptake studies by Rasch and Norgaard
have shown that there is no cell proliferation in glomeruli during
the early phase of diabetic renal hypertrophy [5], and more
recently we have reported that the retinoblastoma protein is
unphosphorylated in diabetic glomeruli during this phase, again
suggesting that active cell proliferation is not a feature of early
diabetic glomerular growth [52]. Thus, it is not surprising that we
could not detect any changes in c-myc mRNA levels. Nakamura et
al also studied the effect of uninephrectomy on mRNA levels for
c-myc, and found that mRNA levels did not rise in glomeruli
following uninephrectomy [19], another setting in which glomer-
ular growth is not accompanied by cell proliferation [5].
In summary, the current study establishes that the early phase
of glomerular hypertrophy in experimental type I diabetes melli-
tus is associated with an increase in c-fos and c-jun expression that
is distinct from the pattern that follows uninephrectomy. These
early events may contribute to the link between diabetic glomer-
ular hypertrophy and diabetic glomerular injury.
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